Market Access
Mumbai, India

What India can learn from Kinvard Bio

India needs its own version of pull, designed for an Indian payer mix, an Indian procurement structure, and an Indian distributor network.

News
Keytruda-840x480

Scotland backs three new uses for MSD's Keytruda

Scotland has become the first country in the UK to back NHS funding for the use of Merck & Co/MSD's Keytruda in combination with Eisai's Lenvima as a treatment for advanced or recurrent

News
Copaxone_pack_shot_Teva

EU says Teva blocked generics to MS drug Copaxone

18 months after it opened an investigation into Teva to see if it illegally blocked generic versions of its big-selling multiple sclerosis drug Copaxone, the European Commission has said it

Views & Analysis
compliance

The criticality of compliance

Remaining compliant is imperative to the life sciences industry, so adhering to regulatory requirements is mandatory.

News

Press Releases

Views & Analysis

Market Access
Mumbai, India

What India can learn from Kinvard Bio

India needs its own version of pull, designed for an Indian payer mix, an Indian procurement structure, and an Indian distributor network.

Newsletters and Deep Dive
digital magazine

Webinars

Podcasts

Video

White Papers

Spotlight on
Life Sciences Industry Report Part 1 Download

Life Sciences Industry Report 2025

In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.

Debates & Insight
PMA 2015 2016
Sponsored

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need

Event

Debates & Insight

Partner Content